Cartilage Oligomeric Matrix Protein: A Potential Prognostic Biomarker and Therapeutic Target in Gastric Cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
[METHODS] The research harnessed data from the Cancer Genome Atlas (TCGA) to explore the significance of COMP in GC and its potential as a diagnostic tool.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
COMP was found to be significantly up-regulated in GC cell lines. [CONCLUSIONS] COMP could serve as a prognostic biomarker and a potential therapeutic target for the treatment of GC.
[BACKGROUND] Cartilage oligomeric matrix protein (COMP) is a protein that has been implicated in the development of some tumors, but its exact role in gastric cancer (GC) remains unclear.
- p-value p < 0.05
- p-value p = 0.027
APA
Li D, Lyu G (2025). Cartilage Oligomeric Matrix Protein: A Potential Prognostic Biomarker and Therapeutic Target in Gastric Cancer.. Current medicinal chemistry, 32(38), 8647-8663. https://doi.org/10.2174/0109298673360512250329171036
MLA
Li D, et al.. "Cartilage Oligomeric Matrix Protein: A Potential Prognostic Biomarker and Therapeutic Target in Gastric Cancer.." Current medicinal chemistry, vol. 32, no. 38, 2025, pp. 8647-8663.
PMID
40277122 ↗
Abstract 한글 요약
[BACKGROUND] Cartilage oligomeric matrix protein (COMP) is a protein that has been implicated in the development of some tumors, but its exact role in gastric cancer (GC) remains unclear.
[OBJECTIVE] The study aims to comprehensively examine COMP in GC and to confirm its effects through experimental methods.
[METHODS] The research harnessed data from the Cancer Genome Atlas (TCGA) to explore the significance of COMP in GC and its potential as a diagnostic tool. The study also examined the regulatory networks involving COMP, including its interactions with immune cells, immune checkpoint genes, tumor mutational burden (TMB), microsatellite instability (MSI), and the stemness index based on mRNA expression (mRNAsi). Additionally, the study explored the relationship between COMP expression and drug sensitivity in GC. Genomic variations of COMP in GC were assessed. The expression of COMP was validated by the GEPIA2 tool and confirmed with quantitative reverse transcription PCR (qRT-PCR) in cell lines (normal human gastric epithelial cells GES-1 and GC cell lines AGS and HGC-27).
[RESULTS] Abnormal expression patterns of COMP were observed in various cancers, including GC. Higher levels of COMP in GC were significantly associated with the pathologic T stage and a history of reflux (p < 0.05 for both). Elevated COMP expression was correlated with poorer progression-free survival (PFS) (p = 0.027). COMP expression levels were identified as an independent prognostic factor for GC (p = 0.017). COMP was linked to TCF-dependent signaling in response to ECM receptor interaction, focal adhesion, and other pathways. There was an association between COMP expression and immune infiltration, immune checkpoint genes, TMB/MSI, and mRNAsi in GC. COMP expression was inversely correlated with the sensitivity to several drugs, indicating that higher levels of COMP may reduce the effectiveness of these drugs. COMP was found to be significantly up-regulated in GC cell lines.
[CONCLUSIONS] COMP could serve as a prognostic biomarker and a potential therapeutic target for the treatment of GC.
[OBJECTIVE] The study aims to comprehensively examine COMP in GC and to confirm its effects through experimental methods.
[METHODS] The research harnessed data from the Cancer Genome Atlas (TCGA) to explore the significance of COMP in GC and its potential as a diagnostic tool. The study also examined the regulatory networks involving COMP, including its interactions with immune cells, immune checkpoint genes, tumor mutational burden (TMB), microsatellite instability (MSI), and the stemness index based on mRNA expression (mRNAsi). Additionally, the study explored the relationship between COMP expression and drug sensitivity in GC. Genomic variations of COMP in GC were assessed. The expression of COMP was validated by the GEPIA2 tool and confirmed with quantitative reverse transcription PCR (qRT-PCR) in cell lines (normal human gastric epithelial cells GES-1 and GC cell lines AGS and HGC-27).
[RESULTS] Abnormal expression patterns of COMP were observed in various cancers, including GC. Higher levels of COMP in GC were significantly associated with the pathologic T stage and a history of reflux (p < 0.05 for both). Elevated COMP expression was correlated with poorer progression-free survival (PFS) (p = 0.027). COMP expression levels were identified as an independent prognostic factor for GC (p = 0.017). COMP was linked to TCF-dependent signaling in response to ECM receptor interaction, focal adhesion, and other pathways. There was an association between COMP expression and immune infiltration, immune checkpoint genes, TMB/MSI, and mRNAsi in GC. COMP expression was inversely correlated with the sensitivity to several drugs, indicating that higher levels of COMP may reduce the effectiveness of these drugs. COMP was found to be significantly up-regulated in GC cell lines.
[CONCLUSIONS] COMP could serve as a prognostic biomarker and a potential therapeutic target for the treatment of GC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Comprehensive complication index: A new reporting standard for postoperative complications of free-flap reconstruction in head and neck cancer patients.
- PEGylated Cu-doped WS hybrid nanosheets for targeted multimodal cancer therapy.
- Causes of Death Among Waldenström Macroglobulinemia Patients: A Population-Based Study.
- Cell-Autonomous AR Dependence in Luminal Prostatic Epithelium Governs Survival and Lineage Plasticity.
- Ensemble-learning-assisted exhaled gas disease analysis based on in-situ construction of MOF-derived MO/GaN heterojunction sensor arrays.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.